Day One Announces Pricing of Upsized Initial Public Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/30/2026
- S&P 500 flat as higher bond yields counter tech optimism
- Anthropic prospectus shows $2T IPO ambition, warns of AI 'existential risk'
- Risk appetite remains concentrated in large-cap stocks, Citi says
- Netflix stock: Deutsche Bank gets bullish as valuation leaves room to run
- CarMax shares rise over 2% on strong earnings and revenue beat
- Salesforce agrees to acquire AI research platform Listen Labs
- Workday cuts 2.5% of workforce, revises GAAP margin outlook
- S&P 500 flat as higher bond yields counter tech optimism
- Wells Fargo raises oil price targets citing ongoing supply risks
- Anthropic prospectus shows $2T IPO ambition, warns of AI 'existential risk'
Day One Biopharmaceuticals (DAWN) IPO Opens 56% Higher
May 27, 2021 11:39 AM EDTToday's IPO for Day One Biopharmaceuticals (NASDAQ: DAWN) opened for trading at $25 after pricing 10,000,000 shares of its common stock at a public offering price of $16.00 per share.
J.P. Morgan, Cowen and Piper Sandler are acting as joint bookrunning managers for the offering. Wedbush PacGrow is acting as lead manager for the offering.
Day One is... More
